NOTE - Amoeba - Strong Buy - Initiation of Coverage - TP: €0.72
Amoéba is a cleantech company committed to the ecological transition through two main applications, the objective of which is to reduce the use of chemical products that are devastating for the environment and health. Amoéba's technology is based on the amoeba Willaertia magna, a type of micro-organism that is still little exploited, unlike bacteria, which are essential for wastewater treatment, or yeast. We initiate coverage of Amoéba with a Strong Buy (1) recommendation and a target price of €0.72.Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.